SCHEMBL23158237

SCHEMBL23158237

CN1CC=C(C(N)=O)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13677425 0.82
SCHEMBL9203433 0.81 QDPR (0.42)
Hydrochloric Acid SCHEMBL10418851 0.79 QDPR (0.41)
Hydrochloric Acid SCHEMBL14311881 0.79 QDPR (0.41)
SCHEMBL5203140 0.78 CHRM2 (0.65)
SCHEMBL12918271 0.77 CHRM3 (0.68)
SCHEMBL20334673 0.77 CHRM2 (0.37)
SCHEMBL23178984 0.77 CHRM2 (0.37)
SCHEMBL23735704 0.75 CHRM2 (0.36)
SCHEMBL28303574 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12435087-B2 Modulators of DCN-1 and methods of use thereof CELLARITY, INC. (US) 2025-10-07 US disclosed
US-20250163058-A1 MODULATORS OF DCN-1 AND METHODS OF USE THEREOF THAMES PHARMA PARTNERS 2025-05-22 US disclosed
WO-2025096981-A1 MODULATORS OF DCN-1 AND METHODS OF USE THEREOF CELLARITY, INC. (US) 2025-05-08 WO disclosed
WO-2021057832-A1 KRAS MUTANT PROTEIN INHIBITOR JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2021-04-01 WO disclosed